358 related articles for article (PubMed ID: 32883368)
21. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
[TBL] [Abstract][Full Text] [Related]
22. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
23. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.
Goyal RK; Majeed J; Tonk R; Dhobi M; Patel B; Sharma K; Apparsundaram S
Rev Cardiovasc Med; 2020 Sep; 21(3):365-384. PubMed ID: 33070542
[TBL] [Abstract][Full Text] [Related]
24. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
25. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
26. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
27. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An
Silva JKRD; Figueiredo PLB; Byler KG; Setzer WN
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32408699
[TBL] [Abstract][Full Text] [Related]
28. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
Chakraborti S; Bheemireddy S; Srinivasan N
Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
[TBL] [Abstract][Full Text] [Related]
29. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
30. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells.
Stelzig KE; Canepa-Escaro F; Schiliro M; Berdnikovs S; Prakash YS; Chiarella SE
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1280-L1281. PubMed ID: 32432918
[TBL] [Abstract][Full Text] [Related]
31. Expression Pattern of the SARS-CoV-2 Entry Genes
Liu Y; Qu HQ; Qu J; Tian L; Hakonarson H
Viruses; 2020 Oct; 12(10):. PubMed ID: 33081421
[TBL] [Abstract][Full Text] [Related]
32. Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.
Płonka W; Paneth A; Paneth P
Molecules; 2020 Oct; 25(20):. PubMed ID: 33053830
[TBL] [Abstract][Full Text] [Related]
33. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.
Calligari P; Bobone S; Ricci G; Bocedi A
Viruses; 2020 Apr; 12(4):. PubMed ID: 32295237
[TBL] [Abstract][Full Text] [Related]
34. Purposing Saikosaponins for the treatment of COVID-19.
Bahbah EI; Negida A; Nabet MS
Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
[No Abstract] [Full Text] [Related]
35. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.
Teralı K; Baddal B; Gülcan HO
J Mol Graph Model; 2020 Nov; 100():107697. PubMed ID: 32739642
[TBL] [Abstract][Full Text] [Related]
36. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
37. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking.
Joshi T; Joshi T; Sharma P; Mathpal S; Pundir H; Bhatt V; Chandra S
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4529-4536. PubMed ID: 32373991
[TBL] [Abstract][Full Text] [Related]
38. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
39. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
[TBL] [Abstract][Full Text] [Related]
40. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.
Prasad K; Khatoon F; Rashid S; Ali N; AlAsmari AF; Ahmed MZ; Alqahtani AS; Alqahtani MS; Kumar V
Int J Biol Macromol; 2020 Nov; 163():1-8. PubMed ID: 32599245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
